Although current clinical studies have not directly explored the effect of WZYD on 5-HT receptors, in clinical practice, 5-HT1B/1D1F receptor agonists have been widely used in the treatment of migraines [49]; 5-HT3 receptor antagonists are used for chemotherapy-induced nausea and vomiting [50]; and 5-HT3, 5-HT4, and 5-HT7 receptors are involved in the prevention and treatment of postoperative gastrointestinal dysfunction in patients undergoing thoracoscopy [51]. The gene discussed is HTR3A; the disease is migraine disorder.